Evidence map›Paper›PMID 29440124›Full record

ArticleEMBO reports2018

SORCS1 and SORCS3 control energy balance and orexigenic peptide production.

Aygul Subkhangulova, Anna R Malik, Guido Hermey, Oliver Popp, Gunnar Dittmar, Thomas Rathjen, Matthew N Poy, Alexander Stumpf, Prateep Sanker Beed, Dietmar Schmitz and 2 more

Open access · hybridAbstract read
In one paragraph

Article in EMBO reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Aygul SubkhangulovaMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany Aygul.Subkhangulova@mdc-berlin.de willnow@mdc-berlin.de.ORCID 0000-0001-8843-0678
Anna R MalikMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Guido HermeyInstitute for Molecular and Cellular Cognition, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oliver PoppMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Gunnar DittmarMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Thomas RathjenMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Matthew N PoyMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Alexander StumpfNeuroscience Research Center, Charité - University Medicine, Berlin, Germany.
Prateep Sanker BeedNeuroscience Research Center, Charité - University Medicine, Berlin, Germany.
Dietmar SchmitzNeuroscience Research Center, Charité - University Medicine, Berlin, Germany.
Tilman BreiderhoffMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany.ORCID 0000-0002-1676-7498
Thomas E WillnowMax-Delbrueck-Center for Molecular Medicine, Berlin, Germany Aygul.Subkhangulova@mdc-berlin.de willnow@mdc-berlin.de.ORCID 0000-0001-9515-7921
Max Delbrück Center · DECharité - Universitätsmedizin Berlin · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SORCS1 and SORCS3 are two related sorting receptors expressed in neurons of the arcuate nucleus of the hypothalamus. Using mouse models with individual or dual receptor deficiencies, we document a previously unknown function of these receptors in central control of metabolism. Specifically, SORCS1 and SORCS3 act as intracellular trafficking receptors for tropomyosin-related kinase B to attenuate signaling by brain-derived neurotrophic factor, a potent regulator of energy homeostasis. Loss of the joint action of SORCS1 and SORCS3 in mutant mice results in excessive production of the orexigenic neuropeptide agouti-related peptide and in a state of chronic energy excess characterized by enhanced food intake, decreased locomotor activity, diminished usage of lipids as metabolic fuel, and increased adiposity, albeit at overall reduced body weight. Our findings highlight a novel concept in regulation of the melanocortin system and the role played by trafficking receptors SORCS1 and SORCS3 in this process.

Indexed as

AdiposityAge FactorsAnimalsBody CompositionBrainBrain-Derived Neurotrophic FactorEnergy MetabolismGene ExpressionGenes, ReporterGlucoseHomeostasisHypothalamusMiceMice, KnockoutModels, BiologicalNerve Tissue ProteinsBrain-Derived Neurotrophic FactorGlucoseNerve Tissue ProteinsReceptors, Cell SurfaceSORCS1 protein, mouseSorcs3 protein, mouseadiposityagouti‐related peptidebrain‐derived neurotrophic factorTrkBVPS10P domain receptors

Identifiers

PMID29440124
PMCPMC5891432
OpenAlexW2786103662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.